Serotypes and antimicrobial susceptibilities of 1033 pneumococci isolated from children in Greece during 2001–2004
Pneumococci (n = 1033) isolated in the major paediatric hospitals of Athens during 2001–2004 from children with invasive infections (n = 186), non-invasive infections (n = 641) and healthy carriers (n = 206) were studied. The most prevalent serotypes were serotypes 14 (44.6%), 19F (43.5%) and 6B (22...
Gespeichert in:
| Veröffentlicht in: | Clinical microbiology and infection 2006-05, Vol.12 (5), p.490-493 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 493 |
|---|---|
| container_issue | 5 |
| container_start_page | 490 |
| container_title | Clinical microbiology and infection |
| container_volume | 12 |
| creator | Paraskakis, I. Kafetzis, D.A. Chrisakis, A. Papavasilliou, H. Kirikou, H. Pangalis, A. Tzouvelekis, L.S. Athanasiou, T. Legakis, N.J. |
| description | Pneumococci (n = 1033) isolated in the major paediatric hospitals of Athens during 2001–2004 from children with invasive infections (n = 186), non-invasive infections (n = 641) and healthy carriers (n = 206) were studied. The most prevalent serotypes were serotypes 14 (44.6%), 19F (43.5%) and 6B (22.8%) in invasive, non-invasive and carriage isolates, respectively. Among invasive isolates, the potential coverage by the seven-valent conjugate vaccine was 75.3%. Resistance rates to penicillin, amoxycillin, cefotaxime, erythromycin, co-trimoxazole, clindamycin, tetracycline and chloramphenicol were 44.6%, 2.7%, 1.2%, 43.6%, 43.5%, 12.4%, 34.7% and 5.9%, respectively. The M-phenotype accounted for 68.0% of the erythromycin-resistant isolates. All isolates were susceptible to ofloxacin. |
| doi_str_mv | 10.1111/j.1469-0691.2006.01383.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67911347</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1198743X14620176</els_id><sourcerecordid>67911347</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5373-f1c63019d136a5358cf16a3482dacd97b93d242358b3810e2f6d5119eda36a673</originalsourceid><addsrcrecordid>eNqNkc9u1DAQxiMEon_gFZAvcEuw48RJDhxgBS3Soh4AiZvl2BOYVRIHO4HujXfgDfsknbAremwtWR5pft94Zr4kYYJngs7rXSYK1aRcNSLLOVcZF7KW2fWj5PR_4jHFoqnTqpDfTpKzGHec81zK4mlyIpQqZCn5aTJ_huDn_QSRmdHRnXFAG3yLpmdxiRamGVvscUZCfEctSMmmEZbBW28tMoy-NzM41gU_MPsDexdgZDiyiwBggbkl4PidUZ_i5s9feopnyZPO9BGeH9_z5OuH9182l-n26uLj5u02taWsZNoJqyQXjRNSmVKWte2EMrKoc2esa6q2kS4vckq0shYc8k65kmYGZ0igKnmevDrUnYL_uUCc9YA0Ud-bEfwStaoaIWRxPyiaUtR5yQmsDyCtKMYAnZ4CDibsteB6tUbv9OqAXh3QqzX6nzX6mqQvjn8s7QDuTnj0goCXR8BEa_oumNFivOMqVVHRgrg3B-439rB_cAN6s_20RqR_d9ADrf4XQtDRIowWHAaws3Ye75_mFugVvps</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19518250</pqid></control><display><type>article</type><title>Serotypes and antimicrobial susceptibilities of 1033 pneumococci isolated from children in Greece during 2001–2004</title><source>MEDLINE</source><source>Wiley Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Paraskakis, I. ; Kafetzis, D.A. ; Chrisakis, A. ; Papavasilliou, H. ; Kirikou, H. ; Pangalis, A. ; Tzouvelekis, L.S. ; Athanasiou, T. ; Legakis, N.J.</creator><creatorcontrib>Paraskakis, I. ; Kafetzis, D.A. ; Chrisakis, A. ; Papavasilliou, H. ; Kirikou, H. ; Pangalis, A. ; Tzouvelekis, L.S. ; Athanasiou, T. ; Legakis, N.J. ; on behalf of the National Surveillance Network for Pneumococcal Resistance ; National Surveillance Network for Pneumococcal Resistance</creatorcontrib><description>Pneumococci (n = 1033) isolated in the major paediatric hospitals of Athens during 2001–2004 from children with invasive infections (n = 186), non-invasive infections (n = 641) and healthy carriers (n = 206) were studied. The most prevalent serotypes were serotypes 14 (44.6%), 19F (43.5%) and 6B (22.8%) in invasive, non-invasive and carriage isolates, respectively. Among invasive isolates, the potential coverage by the seven-valent conjugate vaccine was 75.3%. Resistance rates to penicillin, amoxycillin, cefotaxime, erythromycin, co-trimoxazole, clindamycin, tetracycline and chloramphenicol were 44.6%, 2.7%, 1.2%, 43.6%, 43.5%, 12.4%, 34.7% and 5.9%, respectively. The M-phenotype accounted for 68.0% of the erythromycin-resistant isolates. All isolates were susceptible to ofloxacin.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1111/j.1469-0691.2006.01383.x</identifier><identifier>PMID: 16643530</identifier><language>eng</language><publisher>Oxford, UK: Elsevier Ltd</publisher><subject>Adolescent ; Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Antibiotic susceptibilities ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacterial diseases ; Biological and medical sciences ; Child ; Child, Preschool ; children ; Drug Resistance, Bacterial ; Drug Resistance, Multiple, Bacterial ; Female ; Greece ; Greece - epidemiology ; Human bacterial diseases ; Humans ; Infant ; Infant, Newborn ; Infectious diseases ; Male ; Medical sciences ; Microbial Sensitivity Tests ; Pharmacology. Drug treatments ; Pneumococcal Infections - epidemiology ; Pneumococcal Infections - microbiology ; Pneumococcal Vaccines - immunology ; pneumococci ; serotypes ; Serotyping ; Staphylococcal infections, streptococcal infections, pneumococcal infections ; Streptococcus pneumoniae ; Streptococcus pneumoniae - classification ; Streptococcus pneumoniae - drug effects ; Streptococcus pneumoniae - immunology ; Streptococcus pneumoniae - isolation & purification</subject><ispartof>Clinical microbiology and infection, 2006-05, Vol.12 (5), p.490-493</ispartof><rights>2006 European Society of Clinical Infectious Diseases</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5373-f1c63019d136a5358cf16a3482dacd97b93d242358b3810e2f6d5119eda36a673</citedby><cites>FETCH-LOGICAL-c5373-f1c63019d136a5358cf16a3482dacd97b93d242358b3810e2f6d5119eda36a673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1469-0691.2006.01383.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1469-0691.2006.01383.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17676914$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16643530$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paraskakis, I.</creatorcontrib><creatorcontrib>Kafetzis, D.A.</creatorcontrib><creatorcontrib>Chrisakis, A.</creatorcontrib><creatorcontrib>Papavasilliou, H.</creatorcontrib><creatorcontrib>Kirikou, H.</creatorcontrib><creatorcontrib>Pangalis, A.</creatorcontrib><creatorcontrib>Tzouvelekis, L.S.</creatorcontrib><creatorcontrib>Athanasiou, T.</creatorcontrib><creatorcontrib>Legakis, N.J.</creatorcontrib><creatorcontrib>on behalf of the National Surveillance Network for Pneumococcal Resistance</creatorcontrib><creatorcontrib>National Surveillance Network for Pneumococcal Resistance</creatorcontrib><title>Serotypes and antimicrobial susceptibilities of 1033 pneumococci isolated from children in Greece during 2001–2004</title><title>Clinical microbiology and infection</title><addtitle>Clin Microbiol Infect</addtitle><description>Pneumococci (n = 1033) isolated in the major paediatric hospitals of Athens during 2001–2004 from children with invasive infections (n = 186), non-invasive infections (n = 641) and healthy carriers (n = 206) were studied. The most prevalent serotypes were serotypes 14 (44.6%), 19F (43.5%) and 6B (22.8%) in invasive, non-invasive and carriage isolates, respectively. Among invasive isolates, the potential coverage by the seven-valent conjugate vaccine was 75.3%. Resistance rates to penicillin, amoxycillin, cefotaxime, erythromycin, co-trimoxazole, clindamycin, tetracycline and chloramphenicol were 44.6%, 2.7%, 1.2%, 43.6%, 43.5%, 12.4%, 34.7% and 5.9%, respectively. The M-phenotype accounted for 68.0% of the erythromycin-resistant isolates. All isolates were susceptible to ofloxacin.</description><subject>Adolescent</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotic susceptibilities</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>children</subject><subject>Drug Resistance, Bacterial</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Female</subject><subject>Greece</subject><subject>Greece - epidemiology</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumococcal Infections - epidemiology</subject><subject>Pneumococcal Infections - microbiology</subject><subject>Pneumococcal Vaccines - immunology</subject><subject>pneumococci</subject><subject>serotypes</subject><subject>Serotyping</subject><subject>Staphylococcal infections, streptococcal infections, pneumococcal infections</subject><subject>Streptococcus pneumoniae</subject><subject>Streptococcus pneumoniae - classification</subject><subject>Streptococcus pneumoniae - drug effects</subject><subject>Streptococcus pneumoniae - immunology</subject><subject>Streptococcus pneumoniae - isolation & purification</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9u1DAQxiMEon_gFZAvcEuw48RJDhxgBS3Soh4AiZvl2BOYVRIHO4HujXfgDfsknbAremwtWR5pft94Zr4kYYJngs7rXSYK1aRcNSLLOVcZF7KW2fWj5PR_4jHFoqnTqpDfTpKzGHec81zK4mlyIpQqZCn5aTJ_huDn_QSRmdHRnXFAG3yLpmdxiRamGVvscUZCfEctSMmmEZbBW28tMoy-NzM41gU_MPsDexdgZDiyiwBggbkl4PidUZ_i5s9feopnyZPO9BGeH9_z5OuH9182l-n26uLj5u02taWsZNoJqyQXjRNSmVKWte2EMrKoc2esa6q2kS4vckq0shYc8k65kmYGZ0igKnmevDrUnYL_uUCc9YA0Ud-bEfwStaoaIWRxPyiaUtR5yQmsDyCtKMYAnZ4CDibsteB6tUbv9OqAXh3QqzX6nzX6mqQvjn8s7QDuTnj0goCXR8BEa_oumNFivOMqVVHRgrg3B-439rB_cAN6s_20RqR_d9ADrf4XQtDRIowWHAaws3Ye75_mFugVvps</recordid><startdate>200605</startdate><enddate>200605</enddate><creator>Paraskakis, I.</creator><creator>Kafetzis, D.A.</creator><creator>Chrisakis, A.</creator><creator>Papavasilliou, H.</creator><creator>Kirikou, H.</creator><creator>Pangalis, A.</creator><creator>Tzouvelekis, L.S.</creator><creator>Athanasiou, T.</creator><creator>Legakis, N.J.</creator><general>Elsevier Ltd</general><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200605</creationdate><title>Serotypes and antimicrobial susceptibilities of 1033 pneumococci isolated from children in Greece during 2001–2004</title><author>Paraskakis, I. ; Kafetzis, D.A. ; Chrisakis, A. ; Papavasilliou, H. ; Kirikou, H. ; Pangalis, A. ; Tzouvelekis, L.S. ; Athanasiou, T. ; Legakis, N.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5373-f1c63019d136a5358cf16a3482dacd97b93d242358b3810e2f6d5119eda36a673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adolescent</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotic susceptibilities</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>children</topic><topic>Drug Resistance, Bacterial</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Female</topic><topic>Greece</topic><topic>Greece - epidemiology</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumococcal Infections - epidemiology</topic><topic>Pneumococcal Infections - microbiology</topic><topic>Pneumococcal Vaccines - immunology</topic><topic>pneumococci</topic><topic>serotypes</topic><topic>Serotyping</topic><topic>Staphylococcal infections, streptococcal infections, pneumococcal infections</topic><topic>Streptococcus pneumoniae</topic><topic>Streptococcus pneumoniae - classification</topic><topic>Streptococcus pneumoniae - drug effects</topic><topic>Streptococcus pneumoniae - immunology</topic><topic>Streptococcus pneumoniae - isolation & purification</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paraskakis, I.</creatorcontrib><creatorcontrib>Kafetzis, D.A.</creatorcontrib><creatorcontrib>Chrisakis, A.</creatorcontrib><creatorcontrib>Papavasilliou, H.</creatorcontrib><creatorcontrib>Kirikou, H.</creatorcontrib><creatorcontrib>Pangalis, A.</creatorcontrib><creatorcontrib>Tzouvelekis, L.S.</creatorcontrib><creatorcontrib>Athanasiou, T.</creatorcontrib><creatorcontrib>Legakis, N.J.</creatorcontrib><creatorcontrib>on behalf of the National Surveillance Network for Pneumococcal Resistance</creatorcontrib><creatorcontrib>National Surveillance Network for Pneumococcal Resistance</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paraskakis, I.</au><au>Kafetzis, D.A.</au><au>Chrisakis, A.</au><au>Papavasilliou, H.</au><au>Kirikou, H.</au><au>Pangalis, A.</au><au>Tzouvelekis, L.S.</au><au>Athanasiou, T.</au><au>Legakis, N.J.</au><aucorp>on behalf of the National Surveillance Network for Pneumococcal Resistance</aucorp><aucorp>National Surveillance Network for Pneumococcal Resistance</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serotypes and antimicrobial susceptibilities of 1033 pneumococci isolated from children in Greece during 2001–2004</atitle><jtitle>Clinical microbiology and infection</jtitle><addtitle>Clin Microbiol Infect</addtitle><date>2006-05</date><risdate>2006</risdate><volume>12</volume><issue>5</issue><spage>490</spage><epage>493</epage><pages>490-493</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>Pneumococci (n = 1033) isolated in the major paediatric hospitals of Athens during 2001–2004 from children with invasive infections (n = 186), non-invasive infections (n = 641) and healthy carriers (n = 206) were studied. The most prevalent serotypes were serotypes 14 (44.6%), 19F (43.5%) and 6B (22.8%) in invasive, non-invasive and carriage isolates, respectively. Among invasive isolates, the potential coverage by the seven-valent conjugate vaccine was 75.3%. Resistance rates to penicillin, amoxycillin, cefotaxime, erythromycin, co-trimoxazole, clindamycin, tetracycline and chloramphenicol were 44.6%, 2.7%, 1.2%, 43.6%, 43.5%, 12.4%, 34.7% and 5.9%, respectively. The M-phenotype accounted for 68.0% of the erythromycin-resistant isolates. All isolates were susceptible to ofloxacin.</abstract><cop>Oxford, UK</cop><pub>Elsevier Ltd</pub><pmid>16643530</pmid><doi>10.1111/j.1469-0691.2006.01383.x</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1198-743X |
| ispartof | Clinical microbiology and infection, 2006-05, Vol.12 (5), p.490-493 |
| issn | 1198-743X 1469-0691 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67911347 |
| source | MEDLINE; Wiley Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adolescent Anti-Bacterial Agents - pharmacology Antibacterial agents Antibiotic susceptibilities Antibiotics. Antiinfectious agents. Antiparasitic agents Bacterial diseases Biological and medical sciences Child Child, Preschool children Drug Resistance, Bacterial Drug Resistance, Multiple, Bacterial Female Greece Greece - epidemiology Human bacterial diseases Humans Infant Infant, Newborn Infectious diseases Male Medical sciences Microbial Sensitivity Tests Pharmacology. Drug treatments Pneumococcal Infections - epidemiology Pneumococcal Infections - microbiology Pneumococcal Vaccines - immunology pneumococci serotypes Serotyping Staphylococcal infections, streptococcal infections, pneumococcal infections Streptococcus pneumoniae Streptococcus pneumoniae - classification Streptococcus pneumoniae - drug effects Streptococcus pneumoniae - immunology Streptococcus pneumoniae - isolation & purification |
| title | Serotypes and antimicrobial susceptibilities of 1033 pneumococci isolated from children in Greece during 2001–2004 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T09%3A19%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serotypes%20and%20antimicrobial%20susceptibilities%20of%201033%20pneumococci%20isolated%20from%20children%20in%20Greece%20during%202001%E2%80%932004&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=Paraskakis,%20I.&rft.aucorp=on%20behalf%20of%20the%20National%20Surveillance%20Network%20for%20Pneumococcal%20Resistance&rft.date=2006-05&rft.volume=12&rft.issue=5&rft.spage=490&rft.epage=493&rft.pages=490-493&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1111/j.1469-0691.2006.01383.x&rft_dat=%3Cproquest_cross%3E67911347%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19518250&rft_id=info:pmid/16643530&rft_els_id=S1198743X14620176&rfr_iscdi=true |